Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Parallel Study With an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Parallel Study With an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Testosterone (Primary)
  • Indications Hypogonadism
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 Nov 2016 Results assessing efficacy and safety of testosterone at nine months from 6-months open label extension published in the Journal of Urology.
    • 15 May 2016 Planned locations also included Brazil and Russia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top